706 - Real-world patient experience of upadacitinib-treated adults with atopic dermatitis: results from the SCALE-UP study
Silverberg J, Calimlim B, Fuxench Z, Altman K, Bensimon A, Liu J, Bunick C. 706 - Real-world patient experience of upadacitinib-treated adults with atopic dermatitis: results from the SCALE-UP study. British Journal Of Dermatology 2024, 191: ljae266.080. DOI: 10.1093/bjd/ljae266.080.Peer-Reviewed Original ResearchPatient support programAtopic dermatitisItch improvementSkin clearanceOral Janus kinase inhibitorPatient experiencePhase 3 clinical trialsTreating moderate-to-severe ADEffect of upadacitinibMultiple phase 3 clinical trialsModerate-to-severe ADJanus kinase inhibitorsClinical trial resultsPatient-reported experiencesDecreased quality of lifeEvaluate patient experiencePatient-reported outcomesTopical corticosteroidsPatient ageCross-sectional analysisQuality of lifeUpadacitinib dosesKinase inhibitorsUpadacitinibTreatment duration699 - Prevalence and incidence of atopic dermatitis in patients with alopecia areata in the United States: a population-based study
Mostaghimi A, Armstrong A, Grada A, Soliman A, Li C, C Bristow C, Lipiszko D, Silverberg J, Issa N, Bunick C. 699 - Prevalence and incidence of atopic dermatitis in patients with alopecia areata in the United States: a population-based study. British Journal Of Dermatology 2024, 191: ljae266.073. DOI: 10.1093/bjd/ljae266.073.Peer-Reviewed Original ResearchPost-index dateCharlson Comorbidity IndexModerate-to-severe ADMild AAModerate-to-severe AASevere AAModerate-to-severeAlopecia areataAtopic dermatitisMarketScan Commercial ClaimsTopical corticosteroidsAlopecia totalisReal-world prevalenceIndex dateAlopecia universalisHigh-potency topical corticosteroidsMonths post-index dateAA disease severityIncidence of atopic dermatitisHighest prevalencePotency topical corticosteroidsUS administrative claims databasePrevalence of AACox proportional hazards modelsAD comorbidity